Cargando…

Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients

BACKGROUND: It is not clear how the pathology, presentation and outcome for patients who present with de novo metastatic breast cancer (dnMBC) compare with those who later develop distant metastases. DnMBC is uncommon in younger patients. We describe these differences within a cohort of young patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	McKenzie, Hayley S., Maishman, Tom, Simmonds, Peter, Durcan, Lorraine, Eccles, Diana, Copson, Ellen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250836/ https://www.ncbi.nlm.nih.gov/pubmed/32231292 http://dx.doi.org/10.1038/s41416-020-0784-z

Ejemplares similares

Local Recurrence and Breast Oncological Surgery in Young Women With Breast Cancer: The POSH Observational Cohort Study
por: Maishman, Tom, et al.
Publicado: (2017)

A review of the online prognositc model predict using the POSH cohort (women aged ≤40 years at breast cancer diagnosis)
por: Maishman, Tom, et al.
Publicado: (2015)

Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study
por: Copson, E, et al.
Publicado: (2014)

An evaluation of the prognostic model PREDICT using the POSH cohort of women aged ⩽40 years at breast cancer diagnosis
por: Maishman, T, et al.
Publicado: (2015)

Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
por: Copson, Ellen R, et al.
Publicado: (2018)

Understanding of BRCA VUS genetic results by breast cancer specialists
por: Eccles, B. K., et al.
Publicado: (2015)

Prospective Study of Outcome in Sporadic versus Hereditary Breast Cancer: pros and cons of running a cohort study
por: Gerty, SM, et al.
Publicado: (2008)

Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women
por: Kadalayil, Latha, et al.
Publicado: (2017)

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
por: Tripathy, Debu, et al.
Publicado: (2019)

High-grade ER-negative tumour breast cancers are characteristic of both very young onset cases and patients with hereditary breast cancer
por: Eccles, D, et al.
Publicado: (2006)

Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2020)

Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010
por: Malmgren, Judith A., et al.
Publicado: (2017)

Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study
por: Miotke, Laura, et al.
Publicado: (2022)

Clinical Characteristics and Survival Outcomes of Patients with De Novo Metastatic Breast Cancer
por: Almasri, Hanan, et al.
Publicado: (2022)

Conditional Survival in de novo Metastatic Urothelial Carcinoma
por: Pal, Sumanta Kumar, et al.
Publicado: (2015)

Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non–Small Cell Lung Cancer
por: Su, Chloe C., et al.
Publicado: (2023)

Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer
por: Barcenas, Carlos H., et al.
Publicado: (2021)

De novo and recurrent metastatic breast cancer – A systematic review of population-level changes in survival since 1995
por: Lord, SJ, et al.
Publicado: (2022)

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer
por: Yardley, Denise A., et al.
Publicado: (2014)

Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers
por: McCrorie, Alan D, et al.
Publicado: (2020)

Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol
por: Eccles, Diana, et al.
Publicado: (2007)

Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
por: Lobbezoo, D J A, et al.
Publicado: (2015)

Changes in survival in de novo metastatic cancer in an era of new medicines
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers
por: Copson, Ellen R, et al.
Publicado: (2006)

A Review of Modifiable Risk Factors in Young Women for the Prevention of Breast Cancer
por: Daly, Alex A, et al.
Publicado: (2021)

Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer
por: Pal, Sumanta K, et al.
Publicado: (2012)

Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer
por: Iwase, Toshiaki, et al.
Publicado: (2021)

Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy
por: Corsini, Christian, et al.
Publicado: (2023)

Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy
por: Hu, Y.-J., et al.
Publicado: (2023)

De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer
por: Bozorgmehr, Farastuk, et al.
Publicado: (2021)

The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer
por: Tapper, William, et al.
Publicado: (2008)

Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma
por: Hong, Shaodong, et al.
Publicado: (2016)

Duration of Symptoms, Clinical Staging and Survival in Cancer of Certain Sites
por: McKenzie, A.
Publicado: (1956)

Out of the mouths of researchers: experiences of involvement
por: McKenzie, Anne, et al.
Publicado: (2017)

Mindfulness for the Self-Management of Fatigue, Anxiety, and Depression in Women With Metastatic Breast Cancer: A Mixed Methods Feasibility Study
por: Eyles, Caroline, et al.
Publicado: (2015)

Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era
por: Pal, Sumanta K., et al.
Publicado: (2013)

Predicting Survival of De Novo Metastatic Breast Cancer in Asian Women: Systematic Review and Validation Study
por: Miao, Hui, et al.
Publicado: (2014)

Survival Impact of Nephroureterectomy for De Novo Stage IV Nonmetastatic and Metastatic Upper Tract Urothelial Carcinoma
por: Lin, Wei-Yu, et al.
Publicado: (2022)

Development and validation of nomograms for predicting survival in patients with de novo metastatic triple-negative breast cancer
por: Chen, Mao-Shan, et al.
Publicado: (2022)

Regional location of lymph node metastases predicts survival in patients with de novo metastatic prostate cancer
por: Wang, Zhi-Peng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ojk28g3thcpfcjt3veabk3sa07